Nanotechnology Now - Press Release: Gold Nanorods Hitch Ride on Immune Cells that Target Breast Tumors

Home > Press > Gold Nanorods Hitch Ride on Immune Cells that Target Breast Tumors

Abstract:
One of the challenges in treating cancer, whether using nanotechnology or not, is that tumors can often be inaccessible to the therapies designed to kill them. Mostafa El-Sayed, of the Georgia Institute of Technology, and his colleagues are attempting to overcome this obstacle by designing drug-loaded gold nanorods that attract the attention of tumor-associated immune cells known as macrophages. The researchers believe that these macrophages will then deliver the nanorods to the tumors, crossing the normally impermeable blood-brain barrier to do so.

Gold Nanorods Hitch Ride on Immune Cells that Target Breast Tumors

Bethesda, MD | Posted on August 21st, 2012

Dr. El-Sayed, who is a co-principal investigator of a Cancer Nanotechnology Platform Partnership held jointly by Georgia Tech and Emory University, and his colleagues have synthesized gold nanorods that target tumor-associated macrophages. The investigators have published the initial results of their work in the journal Small.

To attract the attention of tumor-associated macrophages, Dr. El-Sayed's team coated them with an antibiotic belonging to a family of molecules called macrolides. These broad-spectrum antibiotics are known to accumulate at very high concentrations inside macrophages. Therefore, when macrolide-coated nanorods were added to macrophages growing in culture along with breast tumor cells, the macrophages quickly took up the nanorods. When the investigators then irradiated the nanorod-loaded macrophages with light from a near-infrared laser, they found that the co-cultured breast tumor cells, which were not directly exposed to the nanorods, were killed. The researchers hypothesize that the light-activated gold nanorods enhanced the innate tumor-killing activity of the macrophages.

The investigators note that "the ability of tumor-associated macrophages to migrate freely in circulation, bypass the blood-brain barrier, and preferentially accumulate and infiltrate into solid tumors make macrolide-functionalized gold nanoparticles promising candidates for targeted cancer drug delivery to breast and brain tumors." They also hypothesize that this type of therapy could operate synergistically with conventional chemotherapy.

####

About The National Cancer Institute (NCI)
To help meet the goal of reducing the burden of cancer, the National Cancer Institute (NCI), part of the National Institutes of Health, is engaged in efforts to harness the power of nanotechnology to radically change the way we diagnose, treat and prevent cancer.

The NCI Alliance for Nanotechnology in Cancer is a comprehensive, systematized initiative encompassing the public and private sectors, designed to accelerate the application of the best capabilities of nanotechnology to cancer.

Currently, scientists are limited in their ability to turn promising molecular discoveries into benefits for cancer patients. Nanotechnology can provide the technical power and tools that will enable those developing new diagnostics, therapeutics, and preventives to keep pace with today’s explosion in knowledge.

For more information, please click here

Contacts:
National Cancer Institute
Office of Technology & Industrial Relations
ATTN: NCI Alliance for Nanotechnology in Cancer
Building 31, Room 10A49
31 Center Drive , MSC 2580
Bethesda , MD 20892-2580

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: